Continuous Glucose Monitor Patent Landscape 2026
Continuous Glucose Monitor Patent Landscape in 2026
The continuous glucose monitor space is heavily concentrated, with Dexcom holding a dominant position among a small group of established medical-device and diagnostics companies. Activity peaked in 2021 and has eased since, with the field now exhibiting mature-market characteristics—intense competition in core sensing and delivery, but identifiable adjacent branches in digital processing and wireless connectivity that remain comparatively sparse.
Dexcom leads a tightly held field among specialized diabetes-device companies
Dexcom ranks first among the top hundred filers with 1,660 patent records, nearly double the second-ranked Medtronic MiniMed (863 patent records). The top five applicants together account for 47% of the combined total of the hundred largest filers, signaling a high degree of concentration at the leading edge.
A clear two-tier structure is visible: Dexcom and Medtronic MiniMed hold a substantial gap over the next cluster—Insulet (668), F. Hoffmann-La Roche (462), and Abbott Diabetes Care (417)—while the remaining filers drop off more gradually. This separation makes it difficult for mid-tier players to challenge the top two without significant additional investment.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Dexcom Inc | 1,660 | |
| 2 | Medtronic MiniMed Inc | 863 | |
| 3 | Insulet Corporation | 668 | |
| 4 | F HOFFMANN LA ROCHE & CO AG | 462 | |
| 5 | Abbott Diabetes Care Inc | 417 | |
| 6 | Tandem Diabetes Care Inc | 326 | |
| 7 | Bigfoot Biomedical Inc | 314 | |
| 8 | Roche Diabetes Care Inc | 310 | |
| 9 | Roche Diabetes Care GmbH | 294 | |
| 10 | University of Virginia Patent Foundation | 224 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Ascensia Diabetes Care Holdings AG | 208 | |
| 12 | DEKA Products LP | 195 | |
| 13 | BECTON DICKINSON & CO | 156 | |
| 14 | Beta Bionics Inc | 146 | |
| 15 | Biolinq Inc | 141 | |
| 16 | Biosense Webster (Israel) Ltd | 123 | |
| 17 | Animas Corporation | 114 | |
| 18 | Allez Health Inc | 102 | |
| 19 | Roche Diagnostics GmbH | 92 | |
| 20 | Novo Nordisk A/S | 81 |
Dexcom’s lead, built primarily on diagnosis-and-surgery (A61B) and healthcare-informatics (G16H) filings, reflects a strategy spanning both the sensing hardware and the data-management layer. Medtronic MiniMed’s portfolio is more evenly split across sensing and drug-delivery device classes (A61M), suggesting a closed-loop system emphasis rather than sensor-only competition.
Filing counts for 2024–2026 are subject to publication lag and should be treated as preliminary; the apparent decline in those years does not necessarily reflect reduced R&D activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2021; the technology mix is anchored in clinical sensing with growing digital and connectivity branches
The annual filing trend and the IPC branch breakdown together reveal a field that built up rapidly through 2021 and has since moderated, while the technology footprint has expanded beyond pure sensor hardware into informatics, data processing, and wireless communication.
Annual filing trend
Filings grew from 559 records in 2017 to a peak of 939 in 2021, then declined to 779 (2022), 748 (2023), and 609 (2024). The 2025–2026 figures reflect early-publication data only and should not be interpreted as a further structural decline. The multi-year period from 2017 to 2021 represents genuine expansion; the post-2021 easing is consistent with a maturing, consolidating market.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) and A61M (Devices for body fluids) dominate the branch mix, reflecting the core sensor-and-delivery hardware focus. G16H (Healthcare informatics) is the third-largest branch, confirming that data management and clinical decision support have become integral to CGM intellectual property. Lower-density branches including G06F (Electric digital data processing), H04W (Wireless communication networks), and H04L (Digital information transmission) represent a smaller but growing portion of filings, pointing to emerging activity in connectivity and AI-driven analytics.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable continuous glucose monitor device
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Integrated delivery device for continuous glucose … | 2,228 |
| 2 | Signal processing for continuous analyte sensor | 1,805 |
| 3 | System for monitoring physiological characteristics | 1,401 |
| 4 | System for monitoring physiological characteristics | 1,364 |
| 5 | Integrated medicament delivery device for use with… | 1,354 |
| 6 | Analyte sensor | 1,354 |
| 7 | Integrated delivery device for continuous glucose … | 1,345 |
| 8 | Integrated medicament delivery device for use with… | 1,279 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
The combination of high concentration, a post-peak filing trend, strong Roche-entity collaboration, and US-centric geography defines a field where differentiation increasingly depends on software, connectivity, and international filing strategy.
Post-peak consolidation phase with core IP well-defended
Annual volume peaked in 2021 and has eased since, consistent with a market moving from expansion into consolidation. The dominant IPC classes—clinical sensing and drug-delivery devices—are deeply covered by established filers. New entrants face substantial freedom-to-operate challenges in hardware and should focus on adjacent layers such as informatics and connectivity where density is lower.
Lifecycle: post-peakNear-duopoly at the top with a distinct second tier
Dexcom and Medtronic MiniMed together hold a commanding position, accounting for a combined 2,523 patent records ahead of a second tier of Insulet, Roche, and Abbott. The top five filers’ 47% share of the hundred largest filers’ total indicates that any newcomer entering the core sensing or closed-loop delivery space will face extensive overlap with these incumbents. Competitive entry is more viable in informatics, AI, or wireless sub-fields where incumbent density is lower.
High concentrationRoche entities drive the largest co-filing networks; Dexcom partners with Verily and University of Padua
The most active co-filing relationships are within the Roche corporate family: F. Hoffmann-La Roche co-files most heavily with Roche Diabetes Care Inc (136 records), Roche Diagnostics Operations (112 records), and Roche Diabetes Care GmbH (32 records). Abbott Diabetes Care co-files with Cambridge Enterprise (18 records), reflecting an academic-industry bridge. Dexcom co-files with Verily Life Sciences and the University of Padua (4 records each), signaling interest in tech-company and academic partnerships for next-generation sensing.
Intra-group + academicUS-centric filing with selective European and PCT coverage; Asia remains thin
The United States is the primary jurisdiction with 4,368 patent records, followed by the European Patent Office (1,634) and WIPO PCT (1,070). Canada (534) and Australia (485) show meaningful secondary coverage. By contrast, China (63), Japan (109), and South Korea (9) are notably sparse relative to the commercial scale of those diabetes markets, suggesting either a deliberate geographic limitation or an undefended gap that competitors could exploit.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| F. Hoffmann-La Roche & Co. AG | Roche Diabetes Care Inc | 136 |
| F. Hoffmann-La Roche & Co. AG | Roche Diagnostics Operations Inc | 112 |
| F. Hoffmann-La Roche & Co. AG | Roche Diabetes Care GmbH | 32 |
| Roche Diabetes Care Inc | Roche Diabetes Care GmbH | 29 |
| Abbott Diabetes Care Inc | Cambridge Enterprise Ltd | 18 |
| F. Hoffmann-La Roche & Co. AG | Roche Diagnostics GmbH | 6 |
| F. Hoffmann-La Roche & Co. AG | International Business Machines Corporation | 6 |
| Dexcom Inc | Verily Life Sciences LLC | 4 |
| Dexcom Inc | University of Padua | 4 |
| F. Hoffmann-La Roche & Co. AG | Medingo Ltd | 4 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Dexcom leads on sensor IP; Insulet and Abbott show the strongest recent momentum
The top players differ meaningfully in technology emphasis and recent filing trajectories. Dexcom’s scale advantage is clear, but Insulet’s accelerating output and Abbott’s sharp momentum uptick suggest the challenger tier is not static.
Dexcom Inc
Dexcom holds 1,660 patent records—the largest portfolio in the corpus—concentrated in A61B (clinical sensing, 1,550 records) and G16H (healthcare informatics, 443 and 322 records across sub-classes). This breadth across both the sensor hardware and the data-management layer provides a multi-layered defensive position. Recent filing momentum is down 17% versus the prior period, consistent with a mature portfolio entering optimization rather than expansion mode.
patent records: 1,660Insulet Corporation
Insulet ranks third with 668 patent records, with its portfolio weighted toward A61M (drug-delivery devices, 496 records), reflecting its tubeless pump heritage, complemented by G16H informatics (240 records) and A61B sensing (167 records). Notably, Insulet’s recent filing trend is up 67%, the strongest positive momentum among the top-ranked players, suggesting active investment in expanding its CGM-integrated closed-loop position. Abbott Diabetes Care (417 patent records, +126% recent trend) is the other high-momentum challenger, focused on A61B sensing and G16H informatics.
patent records: 668| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Dexcom Inc | 343 | ▼ -17% |
| Medtronic MiniMed Inc | 163 | ▼ -42% |
| Insulet Corporation | 286 | ▲ +67% |
| Bigfoot Biomedical Inc | 81 | ▼ -39% |
| Abbott Diabetes Care Inc | 86 | ▲ +126% |
| F. Hoffmann-La Roche & Co. AG | 28 | ▬ +4% |
| Tandem Diabetes Care Inc | 106 | ▲ +43% |
| University of Virginia Patent Foundation | 55 | ▲ +28% |
Under-served branches in digital processing and wireless connectivity
Relative to the dominant sensing and delivery classes, several IPC branches covering data processing, connectivity, and analytics show lower filing density. These are observations of relative sparsity; the ones noted below also carry plausible technical value for next-generation CGM systems.
G06F · Electric digital data processing
With 1,195 patent records and a 6% share of the branch mix, G06F covers algorithms, software architectures, and embedded computing relevant to real-time glucose trend prediction and device firmware. This branch is comparatively thin given the commercial importance of signal processing and predictive alerting in CGM. Entrants with strengths in embedded systems or edge-AI could find differentiation here with less overlap against established sensor hardware portfolios.
Search this in Eureka →H04W · Wireless communication networks
H04W (334 patent records, 2% share) and H04L (313 patent records, 2% share) together represent the wireless and digital-transmission layer for CGM data relay to smartphones, pumps, and cloud platforms. As CGM integration with wearables and remote patient-monitoring ecosystems grows, robust wireless IP becomes a meaningful competitive asset. The current low density in these branches relative to core sensing classes suggests an entry path for companies with wireless or IoT expertise who can combine connectivity IP with clinical CGM applications.
Search this in Eureka →How leaders differ across sensing, delivery, and informatics routes
Strength of each leader across the main technology routes.
| Player | A61B 5 · Diagnosis & surgery | A61M 5 · Devices for body fluids | G16H 20 · Healthcare informatics | G16H 40 · Healthcare informatics | G16H 50 · Healthcare informatics |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 1,550 | Emerging · 299 | Moderate · 322 | Moderate · 443 | Emerging · 200 |
| Medtronic MiniMed Inc | Strong · 540 | Strong · 443 | Moderate · 206 | Moderate · 129 | Emerging · 82 |
| Insulet Corporation | Moderate · 167 | Strong · 496 | Moderate · 240 | Moderate · 145 | Emerging · 61 |
| Bigfoot Biomedical Inc | Strong · 222 | Strong · 368 | Strong · 210 | Moderate · 153 | Moderate · 98 |
| Abbott Diabetes Care Inc | Strong · 358 | Absent | Moderate · 118 | Moderate · 100 | Moderate · 106 |
| F. Hoffmann-La Roche & Co. AG | Strong · 309 | Moderate · 130 | Emerging · 61 | Moderate · 68 | Moderate · 63 |
| Tandem Diabetes Care Inc | Absent | Strong · 314 | Moderate · 109 | Moderate · 72 | Absent |
Frequently asked questions
The analysis covers 6,201 patent families in the continuous glucose monitor corpus.
Dexcom Inc leads with 1,660 patent records among the top-100 filers, nearly double the second-ranked Medtronic MiniMed at 863 patent records.
The field is assessed as post-peak. Annual filings peaked at 939 records in 2021 and have eased since. The most recent years (2024–2026) reflect incomplete publication data and should not be read as a further structural decline.
The United States is the primary filing jurisdiction with 4,368 patent records, followed by the European Patent Office (1,634) and WIPO PCT (1,070). China (63), Japan (109), and South Korea (9) are notably thin relative to the commercial size of those markets.
Abbott Diabetes Care shows the strongest positive momentum at +126% in its recent filing period, followed by Insulet at +67% and Tandem Diabetes Care at +43%. By contrast, Medtronic MiniMed is down 42% and Bigfoot Biomedical down 39%.
Relative to the dominant sensing (A61B) and delivery-device (A61M) classes, the branches G06F (Electric digital data processing, 6% share), H04W (Wireless communication networks, 2%), and H04L (Digital information transmission, 2%) show lower filing density. These adjacent areas in embedded computing, AI-driven analytics, and wireless connectivity are comparatively sparse and may offer differentiation opportunities for entrants with relevant expertise.
Map the patent landscape for your own technology area
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.